Cellectar Biosciences, Inc.
CLRB
$4.84
$0.142.98%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.65M | 2.97M | 6.54M | 7.83M | 6.36M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 6.04M | 6.40M | 12.74M | 13.33M | 13.70M |
Operating Income | -6.04M | -6.40M | -12.74M | -13.33M | -13.70M |
Income Before Tax | -5.45M | -6.60M | -2.29M | -14.66M | -919.40K |
Income Tax Expenses | -- | -- | 66.00K | -- | -- |
Earnings from Continuing Operations | -5.45M | -6.60M | -2.36M | -14.66M | -919.40K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -5.45M | -6.60M | -2.36M | -14.66M | -919.40K |
EBIT | -6.04M | -6.40M | -12.74M | -13.33M | -13.70M |
EBITDA | -5.98M | -6.34M | -12.68M | -13.26M | -13.64M |
EPS Basic | -3.39 | -4.30 | -1.68 | -11.18 | -0.77 |
Normalized Basic EPS | -2.12 | -2.69 | -1.02 | -6.99 | -0.48 |
EPS Diluted | -3.39 | -4.30 | -1.68 | -12.13 | -5.43 |
Normalized Diluted EPS | -2.12 | -2.69 | -1.02 | -6.91 | -0.46 |
Average Basic Shares Outstanding | 1.61M | 1.54M | 1.40M | 1.31M | 1.19M |
Average Diluted Shares Outstanding | 1.61M | 1.54M | 1.40M | 1.33M | 1.25M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |